EpCAM Expression in Lymph Node Metastases of Urothelial Cell Carcinoma of the Bladder: A Pilot Study
暂无分享,去创建一个
[1] S. Rosati,et al. EpCAM Expression in Lymph Node and Bone Metastases of Prostate Carcinoma: A Pilot Study. , 2014, International journal of molecular sciences.
[2] T. Katoh,et al. A Fluorescent Imaging Probe Based on a Macrocyclic Scaffold That Binds to Cellular EpCAM , 2015, Journal of Molecular Evolution.
[3] W. Mackillop,et al. Lymph node counts are valid indicators of the quality of surgical care in bladder cancer: a population-based study. , 2015, Urologic oncology.
[4] D. Rubello,et al. 11C-Choline PET/CT and Bladder Cancer: Lymph Node Metastasis Assessment With Pathological Specimens as Reference Standard , 2015, Clinical nuclear medicine.
[5] M. Wirth,et al. Relationship of the number of removed lymph nodes to bladder cancer and competing mortality after radical cystectomy. , 2014, European urology.
[6] J. Witjes,et al. The impact of the extent of lymphadenectomy on oncologic outcomes in patients undergoing radical cystectomy for bladder cancer: a systematic review. , 2014, European urology.
[7] D. Rubello,et al. Diagnostic Accuracy of 11C-Choline PET/CT in Preoperative Lymph Node Staging of Bladder Cancer: A Systematic Comparison With Contrast-Enhanced CT and Histologic Findings , 2014, Clinical nuclear medicine.
[8] J. Witjes,et al. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. , 2014, European urology.
[9] M. Zeegers,et al. Urinary EpCAM in urothelial bladder cancer patients: characterisation and evaluation of biomarker potential , 2013, British Journal of Cancer.
[10] W. Duan,et al. Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway. , 2013, The international journal of biochemistry & cell biology.
[11] S. Horenblas,et al. Impact of 18F‐fluorodeoxyglucose (FDG)‐positron‐emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle , 2013, BJU international.
[12] V. Goh,et al. Fluorodeoxyglucose positron‐emission tomography (FDG PET)/computed tomography (CT) in bladder cancer , 2013, BJU international.
[13] C. Antke,et al. Is Minimal Residual Lymph Node Disease in Papillary Thyroid Cancer of Prognostic Impact? An Analysis of The Epithelial Cell Adhesion Molecule EpCAM in Lymph Nodes of 40 pN0 Patients , 2013, Pathology & Oncology Research.
[14] Lucia M. A. Crane,et al. Selecting Potential Targetable Biomarkers for Imaging Purposes in Colorectal Cancer Using TArget Selection Criteria (TASC): A Novel Target Identification Tool. , 2011, Translational oncology.
[15] P. Went,et al. EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysis , 2011, Journal of Clinical Pathology.
[16] J. Ludlow,et al. Increased Urothelial Cell Detection in the Primary Bladder Smooth Muscle Cell Cultures with Dual MACS/qRT-PCR Approach , 2011, Applied immunohistochemistry & molecular morphology : AIMM.
[17] J. Cizeau,et al. A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCGrefractory and BCG-intolerant patients , 2010, Drug design, development and therapy.
[18] O. Akin,et al. Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] G. Schaefer,et al. EpCAM overexpression is associated with high-grade urothelial carcinoma in the renal pelvis. , 2008, Anticancer research.
[20] G. Sauter,et al. High Ep-CAM Expression is Associated with Poor Prognosis in Node-positive Breast Cancer , 2004, Breast Cancer Research and Treatment.
[21] G. Schäfer,et al. Overexpression of Epithelial Cell Adhesion Molecule Antigen in Gallbladder Carcinoma Is an Independent Marker for Poor Survival , 2004, Clinical Cancer Research.
[22] Gregor Mikuz,et al. Ep-CAM overexpression in breast cancer as a predictor of survival , 2000, The Lancet.
[23] J. Izbicki,et al. Disseminated tumor cells in lymph nodes as a determinant for survival in surgically resected non-small-cell lung cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] J. Izbicki,et al. Immunohistochemical assessment of individual tumor cells in lymph nodes of patients with non-small-cell lung cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] H. Stein,et al. Ber-EP4: new monoclonal antibody which distinguishes epithelia from mesothelial. , 1990, Journal of clinical pathology.
[26] P. Möller,et al. Immunohistochemical study of the expression of a Mr 34,000 human epithelium-specific surface glycoprotein in normal and malignant tissues. , 1987, Cancer research.